A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's

Trial Details

NCT ID

NCT07217301

Phase

PHASE3

Sponsor

Takeda

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

IBI363
Control Arm

Locations (sample)

Jonesboro, Arkansas, United States|35.8423,-90.70428
Fountain Valley, California, United States|33.70918,-117.95367
Los Alamitos, California, United States|33.80307,-118.07256
Torrance, California, United States|33.83585,-118.34063
Margate, Florida, United States|26.24453,-80.20644

Key Eligibility Criteria

Must be able to understand and willing to sign the written informed consent form (ICF), be able to comply with the visit schedule and related proce…
Male or female participants must be at least 18 years old or the legal age of majority in their country, whichever is greater. For Japan-specific s…
Have locally unresectable advanced or metastatic histologically or cytologically confirmed squamous NSCLC. Mixed small cell carcinoma, or other pat…
Note: For Japan-specific SRI only: Participants' histology is not restricted to squamous NSCLC and may include all metastatic or unresectable solid…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →